FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080645418> ?p ?o ?g. }

• W3080645418 endingPage "267" @default.
• W3080645418 startingPage "261" @default.
• W3080645418 abstract "Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity evaluated by PET-CT and to compare this response with the response seen on MR imaging. 25 Consecutive patients treated with IM (off label use) for locally advanced (N = 12) or recurrent (N = 13) diffuse-type TGCT were included, 15 male and median age at diagnosis 39 (IQR 31–47) years. The knee was most frequently affected (n = 16; 64%). The effect of IM was assessed pre- and post-IM treatment by comparing MR scans and PET-CT. MR scans were assessed by Tumour Volume Score (TVS), an estimation of the tumour volume as a percentage of the total synovial cavity. PET-CT scans were evaluated based on maximum standardized uptake value (SUV-max). Partial response was defined as more than 50% tumour reduction with TVS and a decrease of at least 30% on SUV-max. Median duration of IM treatment was 7.0 (IQR 4.2–11.5) months. Twenty patients (80%) discontinued IM treatment for poor response or intended surgery. Twenty patients experienced an adverse event grade 1–2, three patients grade 3 (creatinine increment, neutropenic sepsis, liver dysfunction). MR assessment of all joints showed 32% (6/19) partial response and 63% (12/19) stable disease, with a mean difference of 12% (P = 0.467; CI -22.4-46.0) TVS between pre- and post-IM and a significant mean difference of 23% (P = 0.021; CI 4.2–21.6) in all knee lesions. PET-CT, all joints, showed a significantly decreased mean difference of 5.3 (P = 0.004; CI 1.9–8.7) SUV-max between pre- and post-IM treatment (58% (11/19) partial response, 37% (7/19) stable disease). No correlation between MR imaging and PET-CT could be appreciated in 15 patients with complete radiological data. This study confirms the moderate radiological response of IM in diffuse-type TGCT. PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment. Its value should be assessed further to validate its efficacy in the objective measurement of biological response in targeted systemic treatment of TGCT." @default.
• W3080645418 created "2020-09-01" @default.
• W3080645418 creator A5004988229 @default.
• W3080645418 creator A5010876882 @default.
• W3080645418 creator A5020344461 @default.
• W3080645418 creator A5042588531 @default.
• W3080645418 creator A5048423025 @default.
• W3080645418 creator A5058045055 @default.
• W3080645418 creator A5060641427 @default.
• W3080645418 creator A5065935459 @default.
• W3080645418 creator A5088859774 @default.
• W3080645418 date "2020-12-01" @default.
• W3080645418 modified "2023-10-18" @default.
• W3080645418 title "The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT" @default.
• W3080645418 cites W1929661134 @default.
• W3080645418 cites W1964698497 @default.
• W3080645418 cites W2034034179 @default.
• W3080645418 cites W2053237929 @default.
• W3080645418 cites W2106631163 @default.
• W3080645418 cites W2146183809 @default.
• W3080645418 cites W2156758289 @default.
• W3080645418 cites W2171405465 @default.
• W3080645418 cites W2214757868 @default.
• W3080645418 cites W2270511696 @default.
• W3080645418 cites W2325862423 @default.
• W3080645418 cites W2413430220 @default.
• W3080645418 cites W2522100588 @default.
• W3080645418 cites W2616888909 @default.
• W3080645418 cites W2810492845 @default.
• W3080645418 cites W2918220922 @default.
• W3080645418 cites W2942308489 @default.
• W3080645418 cites W2951817901 @default.
• W3080645418 cites W2979321327 @default.
• W3080645418 cites W982662479 @default.
• W3080645418 doi "https://doi.org/10.1016/j.suronc.2020.08.030" @default.
• W3080645418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32932224" @default.
• W3080645418 hasPublicationYear "2020" @default.
• W3080645418 type Work @default.
• W3080645418 sameAs 3080645418 @default.
• W3080645418 citedByCount "10" @default.
• W3080645418 countsByYear W30806454182020 @default.
• W3080645418 countsByYear W30806454182022 @default.
• W3080645418 countsByYear W30806454182023 @default.
• W3080645418 crossrefType "journal-article" @default.
• W3080645418 hasAuthorship W3080645418A5004988229 @default.
• W3080645418 hasAuthorship W3080645418A5010876882 @default.
• W3080645418 hasAuthorship W3080645418A5020344461 @default.
• W3080645418 hasAuthorship W3080645418A5042588531 @default.
• W3080645418 hasAuthorship W3080645418A5048423025 @default.
• W3080645418 hasAuthorship W3080645418A5058045055 @default.
• W3080645418 hasAuthorship W3080645418A5060641427 @default.
• W3080645418 hasAuthorship W3080645418A5065935459 @default.
• W3080645418 hasAuthorship W3080645418A5088859774 @default.
• W3080645418 hasBestOaLocation W30806454181 @default.
• W3080645418 hasConcept C126322002 @default.
• W3080645418 hasConcept C126838900 @default.
• W3080645418 hasConcept C143409427 @default.
• W3080645418 hasConcept C197934379 @default.
• W3080645418 hasConcept C2776694085 @default.
• W3080645418 hasConcept C2777583451 @default.
• W3080645418 hasConcept C2778729363 @default.
• W3080645418 hasConcept C2778822529 @default.
• W3080645418 hasConcept C2779984678 @default.
• W3080645418 hasConcept C2989005 @default.
• W3080645418 hasConcept C3019892230 @default.
• W3080645418 hasConcept C71924100 @default.
• W3080645418 hasConceptScore W3080645418C126322002 @default.
• W3080645418 hasConceptScore W3080645418C126838900 @default.
• W3080645418 hasConceptScore W3080645418C143409427 @default.
• W3080645418 hasConceptScore W3080645418C197934379 @default.
• W3080645418 hasConceptScore W3080645418C2776694085 @default.
• W3080645418 hasConceptScore W3080645418C2777583451 @default.
• W3080645418 hasConceptScore W3080645418C2778729363 @default.
• W3080645418 hasConceptScore W3080645418C2778822529 @default.
• W3080645418 hasConceptScore W3080645418C2779984678 @default.
• W3080645418 hasConceptScore W3080645418C2989005 @default.
• W3080645418 hasConceptScore W3080645418C3019892230 @default.
• W3080645418 hasConceptScore W3080645418C71924100 @default.
• W3080645418 hasLocation W30806454181 @default.
• W3080645418 hasLocation W30806454182 @default.
• W3080645418 hasOpenAccess W3080645418 @default.
• W3080645418 hasPrimaryLocation W30806454181 @default.
• W3080645418 hasRelatedWork W1584669207 @default.
• W3080645418 hasRelatedWork W2024340610 @default.
• W3080645418 hasRelatedWork W2024938637 @default.
• W3080645418 hasRelatedWork W2100902854 @default.
• W3080645418 hasRelatedWork W2121180524 @default.
• W3080645418 hasRelatedWork W2899528185 @default.
• W3080645418 hasRelatedWork W2899585536 @default.
• W3080645418 hasRelatedWork W3030034569 @default.
• W3080645418 hasRelatedWork W3031735911 @default.
• W3080645418 hasRelatedWork W3172671185 @default.
• W3080645418 hasVolume "35" @default.
• W3080645418 isParatext "false" @default.
• W3080645418 isRetracted "false" @default.
• W3080645418 magId "3080645418" @default.
• W3080645418 workType "article" @default.